Precision BioSciences saw its stock price advance Monday after the U.S. Food and Drug Administration granted Fast Track designation to PBGENE-DMD, the company s gene editing therapy candidate for Duchenne muscular dystrophy (DMD). Trading in the Nasdaq-listed shares rose 13% on the news.
The Fast Track label is intended to accelerate the development and review process for therapies addressing serious conditions with unmet medical needs. For PBGENE-DMD, the designation will allow the company more streamlined interactions with the FDA as it continues clinical development.
"Fast Track designation is an important regulatory milestone for PBGENE-DMD and reflects the significant unmet need in DMD," said Michael Amoroso, Chief Executive Officer of Precision BioSciences.
Precision BioSciences recently secured Investigational New Drug (IND) clearance for PBGENE-DMD and has outlined plans to launch a Phase 1/2 clinical study, which it has named FUNCTION-DMD. The company develops its in vivo gene editing candidates using its proprietary ARCUS platform.
The company, based in Durham, North Carolina, also announced it will host a virtual event on March 17, 2026. The session will include Dr. Aravindhan Veerapandiyan, Pediatric Neurologist and Associate Professor of Pediatrics at Arkansas Children s Hospital, together with Pat Furlong, Founding President of Parent Project Muscular Dystrophy. Organizers said the event will focus on the Duchenne treatment landscape and provide an overview of the FUNCTION-DMD trial design.
Duchenne muscular dystrophy is a genetic disorder marked by progressive muscle degeneration and weakness, and it primarily affects boys. The Fast Track designation is intended to support development programs addressing such serious conditions.
Summary
Precision BioSciences received FDA Fast Track designation for PBGENE-DMD, a gene editing therapy candidate for Duchenne muscular dystrophy. The company's shares rose following the announcement. PBGENE-DMD has IND clearance and is planned to enter a Phase 1/2 study called FUNCTION-DMD. Precision develops in vivo gene editing treatments using its ARCUS platform and will host a virtual event on March 17, 2026 to discuss the trial and treatment landscape.
Key Points
- Precision BioSciences (NASDAQ:DTIL) shares rose 13% after the FDA granted Fast Track status to PBGENE-DMD.
- The company has IND clearance for PBGENE-DMD and plans a Phase 1/2 trial named FUNCTION-DMD, leveraging its ARCUS in vivo gene editing platform.
- A virtual event on March 17, 2026 will present expert perspectives and an overview of the trial design; this development affects biotech investors and the biotechnology sector more broadly.
Risks and Uncertainties
- Fast Track designation does not guarantee clinical success or regulatory approval - clinical outcomes remain uncertain, which impacts biotech and equity markets tied to clinical milestones.
- Progression from IND clearance to clinical trial initiation and completion carries inherent development and operational risks for the company and for investors in the biotechnology sector.